Navigation Links
Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
Date:5/12/2009

EMERYVILLE, Calif., May 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19, at 2:35 p.m. Eastern Time. Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/wt/page/event_calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through June 19, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
2. Vion Pharmaceuticals Reports 2009 First Quarter Results
3. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
4. Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Photos: Generic Pharmaceuticals Saved $734 Billion over Last Decade
7. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
8. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
10. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
11. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Dr. Edward Hebert is celebrating ... imagine doing anything else,” said Dr. Hebert. “I count my blessings daily for the ... with my patients is what I look forward to the most. The relationships I ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Grandpa's Visit”: a tender and ... share with the others. “Grandpa's Visit” is the creation of published author, Beverly Brumfield, ... is much like the character in her book. She shares, “Mr. Rice is struggling ...
(Date:9/25/2017)... ... , ... The trend-spotters, tastemakers, and healthy lifestyle product experts at the ... drinks, with the new NEXTY Gold Award at the Natural Products Expo East trade ... which is reserved for just those companies that hit high marks on the criteria ...
(Date:9/25/2017)... ... September 25, 2017 , ... Emerald Ash Borers kill Ash trees in as ... throughout the Philadelphia region. A video by Rob Nagy, ISA Certified Arborist at Giroud ... While several are dead or showing signs of decline from Emerald Ash Borers, two ...
(Date:9/24/2017)... ... ... Andrea Purcell, NMD, had an epiphany one evening. Four months pregnant, she sat sobbing at ... pregnancy was so hard. She wondered why no one talks about what it is really ... she decided to write what she wished her friends and colleagues could have told her: ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
(Date:8/31/2017)... , Aug. 31, 2017 PM360,s annual ... guide to the latest innovations happening across the industry. ... publication to focus on providing a comprehensive look at ... issue covers the most innovative companies, startups, divisions, products, ... "Everyone in this industry wants ...
Breaking Medicine Technology: